I’ll have to look at it more closely when I have more time, but this part at the beginning caught my eye.
In the Non-GMP to GMP conversion, there’s quite a big change between the realized numbers of the previous period and the targets for the upcoming period. This creates a significant bottleneck for all other operations, because those GMP projects are the only ones from which any significant sums of money can be obtained.
➢ Nanoform realized number 2020-25: ~5%
➢ Nanoform target for 2030: 20-25%
Why is that figure for the 2020-2025 period so poor, and by what actions is it expected to improve so much? This is probably partly due to the poor funding situation for biotechs during this period, but is it also possible for Nanoform to be more selective with development projects in the future and cut out the weakest projects already at an early stage?